CTNM vs. AKBA, VNDA, XERS, HOWL, VSTM, RAPT, FHTX, PYXS, NBTX, and VRCA
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Akebia Therapeutics (AKBA), Vanda Pharmaceuticals (VNDA), Xeris Biopharma (XERS), Werewolf Therapeutics (HOWL), Verastem (VSTM), RAPT Therapeutics (RAPT), Foghorn Therapeutics (FHTX), Pyxis Oncology (PYXS), Nanobiotix (NBTX), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.8% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Akebia Therapeutics had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for Akebia Therapeutics and 2 mentions for Contineum Therapeutics. Akebia Therapeutics' average media sentiment score of 0.58 beat Contineum Therapeutics' score of 0.21 indicating that Contineum Therapeutics is being referred to more favorably in the news media.
Akebia Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 275.94%. Contineum Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 74.78%. Given Contineum Therapeutics' higher possible upside, research analysts plainly believe Akebia Therapeutics is more favorable than Contineum Therapeutics.
Contineum Therapeutics has a net margin of 0.00% compared to Contineum Therapeutics' net margin of -26.32%.
Akebia Therapeutics received 407 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Contineum Therapeutics has lower revenue, but higher earnings than Akebia Therapeutics.
Summary
Akebia Therapeutics beats Contineum Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
